GROSS LAW FIRM

CorMedix Inc. Loss Submission Form

The Gross Law Firm notifies investors that a class action has commenced in the United States District Court for the District of New Jersey on behalf of shareholders of CorMedix Inc. who purchased shares between October 16, 2019 and May 13, 2021.

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that:

(i) deficiencies existed with respect to an investigational drug product, DefenCath’s, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath’s manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.

Shareholders have until September 20, 2021 to request that the court appoint them lead plaintiff.

To receive more information, please fill out the form.

Name

Email

Physical Address

Phone Number

Shares Owned

Purchase Date

Loss

By submitting your information, it does not create an attorney-client relationship and you are giving us your express consent to contact you by email, text message, SMS, or call you by telephone.

Privacy Notice